99.9% Irbesartan manufacturer plant CAS 138402-11-6

Details:

Zhuhai Rundu Pharmaceutical Co., Ltd. and its wholly-owned subsidiary Zhuhai Sanxin Fine Chemical Co., Ltd. is specialized in R&D, production and sales of pharmaceutical product, gathering a best group of R&D, production and quality management,which laid the good foundation for the enterprise’s development.

Our company covers an area of 100000 square meters, owning: more than 800 employees, The new plant is expected to be put into production in 2016.new pharmaceutical manufacturing center in accordance with national GMP standard, over 10 GMP production lines for six dosage forms of APIs andrelated intermediates, tablet, granule, capsule, injection and pellet intermediates and 52 varieties of registered drugs for cardiovascular and digestive system, anesthesia, respiratory tract and anti-infection system.

Our R&D center has been identified as technology center of Guangdong Province. It is gathering a research group leading by doctors of pharmacy whom already engages in the development of new products and existing products innovation and optimization for many years. Our scientific research advantages: Multiple step chemical synthesis reaction,Hydrogenation reaction and Sustained controlled release pellets.

Our State Category I New Drug-HIGENAMINE will be launched on the market. Profiting from our own technology of sustained controlled release pellets, we have built an automated pellet production line. It has been named as Innovative Industrialization Demonstration base of Guangdong Province. With sugar sphere production license and GMP production lines,our company has realized the full support and supply for high-quality celphere industry taking the advantages of the biggest pellet production base.

Our company has great advantages in SARTAN products for anti-hypertension and proton pump inhibitor series products for anti-ulceration. Our product of Piperaquine Phosphate for anti-malaria has obtained WHO GMP. Valsartan and Irbesartan have completed the registration of Russian and Korean FDA. Candesartan Cilexetil and Olmesartan Medoxomil have obtained CEP certificate, Valsartan and Irbesartan etc. will also obtain CEP shortly.The registrations for European and Japanese markets of related products have achieved preliminary results, Dosage form registrations and market developments have already started as well.

Our company locates in Zhuhai City which is one of the most famous tourist cities in China. Our factory is of garden-like with great production and environmental protection facility. We always provide you with the best quality products.